BONESUPPORT announced 12-month follow-up data from an on-going clinical trial investigating the safety and efficacy of CERAMENT|G in chronic bone infection and the completeness of bone healing after surgery. CERAMENT|G is an injectable antibiotic eluting bone substitute. The results also showed evidence of ongoing bone remodeling in 80 percent of the remaining patients.
“This evidence reinforces our belief that CERAMENT|G has the potential to impact the surgical strategy for managing osteomyelitis, by providing a more effective delivery of antibiotics with concomitant full bone healing in a one-stage procedure, thereby reducing treatment time, minimizing surgical interventions and lowering healthcare costs,” said Lloyd Diamond, CEO of BONESUPPORT.
More articles on devices:
Zimmer purchases biologic therapeutics company ETEX
Medtronic to aid Syrian refugees in Jordan
Bacterin CEO to appear on FOX Business Network’s Open Bell
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
